About Actelion
Actelion is a Healthcare company based in Allschwil (Switzerland) founded in 1997, and was acquired by Johnson & Johnson in January 2017. Innovative treatments for orphan diseases are discovered, developed, and commercialized. Actelion has raised $46 million across 2 funding rounds from investors including Johnson & Johnson, 3i Group and Atlas Venture. Actelion has completed 3 acquisitions, including Axovan, Ceptaris Therapeutics and CoTherix. Its focus areas include Life Sciences, Pulmonology, Drugs and Pulmonary Arterial Hypertension. Its legal entity in India is Actelion Pharmaceuticals India Private Limited (U73100MH2008PTC178647).
Company details
Actelion specializes in small molecule therapeutics for orphan diseases. Actelion scientists were among the first to work in the field of endothelian receptor antagonists. Actelion has 29 operative affiliates around the world, including the United States, Canada, Brazil, Australia, Japan, Switzerland and a number of EU countries. Actelion currently has 10 compounds in its pipeline including 3 in late-stage development and 4 medicines on the market for orphan diseases: Tracleer (bosentan), a dual endothelin receptor antagonist which was the first oral treatment approved for pulmonary arterial hypertension; Zavesca (miglustat), currently the only approved oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Ventavis (iloprost), indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) in patients with NYHA Class III or IV symptoms; Veletri (epoprostenol for injection), approved for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.
- Headquarters Allschwil, Switzerland
- Stage Acquired
- SectorsHealthcare
- Website actelion.com
- Social LinkedIn X Instagram YouTube
- Acquired by Johnson & Johnson (Jan 2017)
- Legal Name Actelion Pharmaceuticals India Private Limited
- Date of Incorporation 08 Feb, 2008
- Jurisdiction Mumbai, Maharashtra, India
- Total Equity Funding$46M (USD)
in 2 rounds
- Latest Funding Round$34M (USD), Series B
Mar 1999
- InvestorsJohnson & Johnson
& 5 more
- Investments & AcquisitionsAxovan
& 2 more
- Acquired byJohnson & Johnson
(Jan 2017)
Associated legal entities of Actelion
Actelion operates through Actelion Pharmaceuticals India Private Limited (strike off). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals India Private Limited CIN U73100MH2008PTC178647 | Strike Off | 08 Feb 2008 | Mumbai, Maharashtra | 3 | View details |
Apps and channels of Actelion
its YouTube channel J&J Innovative Medicine has 74.8K subscribers and 30 videos.
Videos from Actelion
The most watched videos on Actelion's YouTube channel, J&J Innovative Medicine (74.8K subscribers). Click a video to play it here.
More on J&J Innovative Medicine.
Funding Insights of Actelion
Actelion has successfully raised a total of $46M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $34 million completed in March 1999. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $46M
- Total Rounds 2
- Last Round Series B — $34M
- First Round $12M
(May 1998)
- Investors Count 5
All 2 funding rounds of Actelion with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 1999 | $34M | Series B | – | – | |
| May 1998 | $12M | Series A | – | 3i Group, TVM Capital | – |
6 investors in total: 6 institutional.
Investors in Actelion
Actelion has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Johnson & Johnson, 3i Group and Atlas Venture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Capital is invested in life science innovations for healthcare transformation. | tvm-capital.com | Munich, Germany | ||
Private equity firm focused on mid-market businesses | 1945 | 3i.com | London, United Kingdom | |
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Stage-agnostic life sciences-focused VC firm investing in North America & Europe | neomed.net | Oslo, Norway | ||
Sofinnova Partners is focused on life sciences and healthcare investments. | sofinnovapartners.com | Paris, France | ||
Healthcare solutions are provided by Johnson & Johnson globally. | 1886 | jnj.com | New Brunswick, United States |
Investor details for Actelion
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Actelion Pharmaceuticals India Private Limited (Actelion)
Actelion Pharmaceuticals India Private Limited is the primary company behind Actelion. The board of Actelion Pharmaceuticals India Private Limited currently have 3 directors; the longest-serving is Miriam Halperin Wernli, appointed in 2008. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Miriam Halperin Wernli DIN 01576111 | Director | 08 Feb 2008 | 18 yrs 8 mo | Actelion Pharmaceuticals India Private Limited |
| Louis Alfred De Lassence DIN 01963901 | Director | 08 Mar 2008 | 18 yrs 7 mo | Actelion Pharmaceuticals India Private Limited |
| Allen Leonard Pickering DIN 06540878 | Director | 30 Mar 2013 | 13 yrs 7 mo | Actelion Pharmaceuticals India Private Limited |
People of Actelion
789 people are tracked at Actelion (353 in leadership, 11 in board & advisors, 425 in team).
| Name | Role | Group |
|---|---|---|
Travis Covington | Vp, Strategic Robotics R&d | Leadership |
Richard Tillyer | Global Head, Discovery, Product Development & Supply, Janssen Research and Development | Leadership |
Thomas O'Gara | Senior Director, Strategic Demand & Capacity Management | Leadership |
Hitesh Vora | Director | Leadership |
Deepak Bandyopadhyay | Director, Data Science, R&d Quality | Leadership |
Sue Hohenleitner | VP, Finance, Johnson & Johnson Innovation | Leadership |
Charles Nau | Director | Leadership |
Anand Narayanan | Director | Leadership |
Neema Kulkarni | Associate Director, Global Topical Healthcare | Leadership |
Alice Pizzelanti | Head Of Hr, Janssen US Commercial Centers Of Excellence | Leadership |
Anuj Terapanthi | IT Director - Platform Leader, Finance Data & Analytics | Leadership |
Chandra Branham | Senior Director, Payment & Care Delivery, Health Policy | Leadership |
Minh Miran | Global Sr. Director, Strategy & Operations | Leadership |
Hoang Lu (Jack) | Director | Leadership |
Bert Bruyninckx | Director | Leadership |
Juan Velez | IT Director | Leadership |
Liz Rivett | Director | Leadership |
Carol Boyne | Director | Leadership |
Wael Adhami | Vice President, Global Trade Controls | Leadership |
Andrea Kollath | Director | Leadership |
769 more people are available in the full profile.
Complete people profiles for Actelion
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Actelion
Actelion has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Axovan, Ceptaris Therapeutics and CoTherix.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Mechlorethamine gel for mycosis fungoides is developed by Ceptaris Therapeutics. | ceptaris.com | Malvern, United States | 2002 | Jul 2013 | $250M | |
Inhaled therapeutics for cardiopulmonary diseases were developed and licensed. | cotherix.com | San Francisco, United States | 2000 | Nov 2006 | $420M | |
Drug development company specializing in G Protein-Coupled Receptors (GPCRs) targeting therapeutics | axovan.com | Allschwil, Switzerland | 2000 | Sep 2003 | $189.89M |
Complete acquisition details for Actelion
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Actelion
8 dated milestones of Actelion across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Actelion is founded.
- Funding First funding round of $12.0M.
- Funding Latest funding round, Series B, of $34.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Axovan.
- Acquisition Acquires CoTherix.
- Acquisition Acquires Ceptaris Therapeutics.
- Exit Acquired by Johnson & Johnson.
Web traffic of Actelion
Websites that share an audience with Actelion (actelion.com).
Websites whose visitors overlap most with Actelion. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| basilea.com | 100% | 7.8K | #2,173,854 | View details | |
| roche.com | 97% | 1.3M | #42,219 | View details | |
| polyphor.com | 92% | View details | |||
| pfizer.com | 90% | 1.9M | #24,984 | View details | |
| merck.com | 78% | 656.8K | #78,842 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 21 similar websites and full traffic analytics for Actelion
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 21 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Actelion
Complete news archive for Actelion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Actelion
Actelion was founded in 1997 and raised its 1st funding round 1 year after it was founded.
Actelion is headquartered in Allschwil, Switzerland. It is registered at Allschwil, Basel-landschaft, Switzerland.
Actelion is a funded company, having raised a total of $46M across 2 funding rounds to date. The company's 1st funding round was a Series A of $12M, raised on May 1998.
Actelion specializes in small molecule therapeutics for orphan diseases. Actelion scientists were among the first to work in the field of endothelian receptor antagonists. Actelion has 29 operative affiliates around the world, including the United States, Canada, Brazil, Australia, Japan, Switzerland and a number of EU countries. Actelion currently has 10 compounds in its pipeline including 3 in late-stage development and 4 medicines on the market for orphan diseases: Tracleer (bosentan), a dual endothelin receptor antagonist which was the first oral treatment approved for pulmonary arterial hypertension; Zavesca (miglustat), currently the only approved oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Ventavis (iloprost), indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) in patients with NYHA Class III or IV symptoms; Veletri (epoprostenol for injection), approved for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.
Actelion has made 3 acquisitions, including Axovan, Ceptaris Therapeutics, and CoTherix.
Actelion has 6 investors. Key investors include Johnson & Johnson, 3i Group, Atlas Venture, TVM Capital Life Science, and NeoMed.
Actelion operates through Actelion Pharmaceuticals India Private Limited.
Yes. Actelion was acquired by Johnson & Johnson in January 2017.
The legal entities of Actelion currently have 3 directors, including Louis Alfred De Lassence, Allen Leonard Pickering, Miriam Halperin Wernli.